Solventum Stock
Solventum Corporation
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Bryan C. Hanson
- Employees
- 20,584
- Market cap
- $14.6 B
- IPO
- 01/04/2024
Solventum Corporation is a healthcare entity headquartered in Eagan, US, and is traded on the NYSE under the ticker symbol SOLV. Established in 2023, the company focuses on pioneering, producing, and commercializing diverse solutions designed to address critical needs for both customers and patients. The business…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Solventum stock: price history
1D
-2.3%
1W
-1.7%
1M
-3.4%
6M
+21.8%
YTD
+8.3%
1Y
+20.1%
2Y
+20.1%
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~59% stronger price swings than usual
Solventum stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Solventum Corporation operates as a provider of diverse medical solutions across surgery, dentistry, information technology, and filtration. The company distributes a broad range of products, including wound care consumables, dental components such as brackets and filling materials, and highly specialized instruments for sterilization and temperature control. A significant business segment is also the provision of software platforms for clinical documentation, billing automation, and data visualization in healthcare. The portfolio is complemented by cleaning and filtration technologies. The business model combines the sale of physical medical products with specialized software-enabled solutions.
- Revenue model
- Mixed
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Solventum
Analyst assessment of Solventum
PRICE TARGET LOW
US$43.00
CONSENSUS
US$91.22
MEDIAN
US$95.00
PRICE TARGET HIGH
US$113.00
0
STRONG BUY
9
BUY
2
HOLD
1
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 14/09/2026
Solventum stock metrics
P/E
10.44
P/B
3.1
EV/EBITDA
7.9
RETURN ON EQUITY
1.9%
NET MARGIN
4.2%
DEBT/EQUITY
1.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
84.9%
FLOAT SHARES
144,580,197
AVG. DAILY VOLUME (30D)
942,259
Insider transactions (SEC)
Hanson Bryan C
Hanson Bryan C
McMillan Wayde D.
McMillan Wayde D.
Kirberger Marcela A.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.3%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Solventum stock
What does Solventum do?
Solventum Corporation is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Bryan C. Hanson, the company employs around 20,584 people.
The IPO was on 01/04/2024; the stock trades on NYSE under the ticker SOLV.
What do analysts say about Solventum stock?
12 analysts rate the stock, the consensus is Buy (as of 14/09/2026).
The average price target is US$91.22, ranging from US$43.00 to US$113.00, with a median of US$95.00.
This is an external assessment, not a statement by Market Jury.
When does Solventum report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 59% stronger than usual.
Does Solventum pay a dividend?
No, Solventum currently does not pay a dividend.
Which stocks are comparable to Solventum?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Baxter International, Cooper Companies, Avantor and Repligen.
How can I get Solventum stock analyzed?
Clicking "Analyze stock" lets five strategies assess Solventum against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.